How Regeneron Pharmaceuticals Went From Cheaper Than Incyte To The Pricier Stock
The market has flipped its preference between two biotech rivals, asking investors to decide what a premium for slower growth is truly buying.
In the biotechnology sector, a dollar of Regeneron (REGN)’s operating profit currently costs an investor 19.6 times, while the same dollar at industry peer Incyte (INCY) costs just 13.2 times. These are two direct ways to own exposure to drug development and commercialization, but the market is pricing them very differently. The core question for any Regeneron investor is what has changed to justify the stock now trading at a premium it did not command a year ago, when its valuation was actually lower than Incyte’s.
Does Regeneron’s Scale and Pipeline Justify the Price?
The case for Regeneron’s premium valuation rests on its sheer scale and the depth of its research engine. With trailing twelve-month revenue of $15.53 billion, Regeneron is a commercial powerhouse built on a portfolio of blockbusters. Its flagship drug Dupixent, in partnership with Sanofi, posted global net product sales of $6 billion in the second quarter alone, a 38% year-over-year increase.
Beyond that, its next-generation eye drug, EYLEA HD, is gaining significant traction, with U.S. net sales hitting nearly $600 million in the second quarter, up 52% from the prior year. Management points to a pipeline with “approximately 50 active clinical programs” as a core strength, arguing this diversification provides many opportunities to create future value. Paying a premium here is a bet on this proven, multi-front machine to continue delivering.
The key numbers side by side, today:
| Metric | REGN | INCY |
|---|---|---|
| P/OpInc* | 19.6x | 13.2x |
| LTM OpInc Growth | 6.1% | 85.0% |
| 3Y Avg OpInc Growth | -1.7% | 552.7% |
| LTM Revenue Growth | 9.3% | 26.9% |
| 3Y Avg Revenue Growth | 7.0% | 18.5% |
OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio
And the same comparison exactly a year ago, so you can see which way the mismatch has been moving:
| Metric | REGN | INCY |
|---|---|---|
| P/OpInc* | 14.8x | 15.9x |
| LTM OpInc Growth | -3.3% | 1660.4% |
| 3Y Avg OpInc Growth | -16.4% | 511.3% |
| LTM Revenue Growth | 5.4% | 18.9% |
| 3Y Avg Revenue Growth | 0.3% | 11.5% |
OpInc = Operating Income
What Does Faster Growth at a Lower Price Look Like?
By paying that premium for Regeneron, an investor gives up the faster growth and higher profitability currently on offer at Incyte. Incyte grew its revenue by 26.9% over the last twelve months, far outpacing Regeneron’s 9.3% growth. It also operates more profitably, with a trailing operating margin of 31.6% versus Regeneron’s 26.9%.
Trailing numbers alone don’t tell the whole story. Incyte recently raised its forward guidance for total net sales, signaling management’s confidence. The company is also executing on its own pipeline, recently securing European Union approval for a topical product for atopic dermatitis. For investors who prefer a simpler thesis, Incyte presents a straightforward case: a faster-growing, more profitable business that the market currently values at a discount to its larger peer.
Is the Choice Between a Proven Fleet and a Faster Ship?
The decision boils down to whether you believe Regeneron’s diversified portfolio and deep pipeline are worth paying up for, even with slower top-line growth. The premium buys you a stake in a large, proven commercial operation with multiple shots on goal, while the cheaper peer offers a more concentrated but faster-moving growth story.
The immediate test for Regeneron’s execution will be the regulatory path for its EYLEA HD prefilled syringe. After a delay, management is now working toward a potential approval “before the end of the year.” Whether the company delivers on that timeline will be a key signal about its ability to execute on the enhancements that justify its premium. The choice is yours.
Rather Compare Them On Your Own Terms?
You can line Regeneron Pharmaceuticals and Incyte up directly on the Regeneron Pharmaceuticals peer comparison, weigh them on valuation, growth, margins, and returns, and swap in any other Biotechnology names you hold. Or, if you would rather not pick a side at all, a biotech ETF like IBB holds both Regeneron Pharmaceuticals and Incyte alongside the rest of the group.
Paying The Right Price For Growth Is The Whole Game
This comparison is one instance of the only question that matters in stock picking: how much growth are you getting per dollar you pay? Most portfolios never ask it systematically, which is why most portfolios trail.
The Trefis High Quality (HQ) Portfolio is that question turned into a machine: roughly 30 businesses screened for real growth at defensible prices, held with discipline. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. You just watched the test run on two stocks; own the version that runs on the whole market.